| Detected | Trial | Change |
|---|---|---|
| 2026-06-02 | NCT04109729 Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant… |
date change Primary completion pushed: 2025-02-18 -> 2026-04-28 |
| 2026-06-02 | NCT04109729 Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant… |
date change Completion pushed: 2026-04-30 -> 2026-12 |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-05-28 | NCT07611110 AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant… | Phase 3 | Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT04597125 | RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs… | Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Active, Not Recruiting |
| Phase 3 | |||
| NCT07611110 | AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant… | Metastatic Castration-resistant Prostate Cancer | Recruiting |
| NCT03574571 | A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer | Prostate Cancer | Active, Not Recruiting |
| Phase 2 | |||
| NCT05924672 | Efficacy of Ra-223 in PSMA PET Optimally Selected Patients | Castration-Resistant Prostate Carcinoma | Active, Not Recruiting |
| NCT04206319 | Radium-223 in Biochemically Recurrent Prostate Cancer | Biochemical Recurrent Prostate Cancer | Active, Not Recruiting |
| Phase 1 | |||
| NCT04109729 | Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant… | Metastatic Castration-resistant Prostate Cancer | Active, Not Recruiting |
| Not specified | |||
| NCT04489719 | Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic… | Castration-Resistant Prostate Carcinoma | Recruiting |